Breaking Down SG&A Expenses: ADMA Biologics, Inc. vs ImmunityBio, Inc.

A Comparative Analysis of SG&A Expenses: ADMA Biologics, Inc. vs ImmunityBio, Inc.

In the competitive landscape of biotechnology, understanding the financial strategies of key players is crucial. Over the past decade, ADMA Biologics, Inc. and ImmunityBio, Inc. have demonstrated distinct approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, growing by approximately 1,100%, reflecting their strategic investments in growth and development. In contrast, ImmunityBio's expenses fluctuated significantly, peaking in 2015 with a staggering 5,200% increase compared to the previous year, before stabilizing in recent years. This divergence highlights the varied financial strategies within the biotech sector, where companies balance between aggressive expansion and sustainable growth. As the industry evolves, these insights provide a window into the financial health and strategic priorities of these innovative firms.